Enterprise Value

1.553B

Cash

1.768B

Avg Qtr Burn

-85.75M

Short % of Float

17.30%

Insider Ownership

1.38%

Institutional Own.

67.47%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

PDUFA

Approval decision

PDUFA

Approval decision

CTX110 (CD19) Details
CD19+ malignancies, Blood cancer, Cancer, B-cell malignancies

Phase 2

Data readout

VCTX211 Details
Type 1 diabetes

Phase 1/2

Data readout

Phase 1/2

Update

Phase 1/2

Update

CTX112 (CD19) Details
CD19+ malignancies, Blood cancer, Cancer, B-cell malignancies

Phase 1

Data readout

VCTX210 Details
Type 1 diabetes

Phase 1

Data readout

CTX131 (CD70) Details
Cancer, Solid tumor/s

Phase 1

Update

CTX130 (CD70) Details
Blood cancer, Cancer, T-cell lymphoma

Phase 1

Update

CTX120 (BCMA) Details
Multiple myeloma, Blood cancer, Cancer

Failed

Discontinued